Background Despite advances in supportive care, sepsis-related mortality remains high, especially in patients with acute kidney injury (AKI). Erythropoietin can protect organs against ischemia and sepsis. This effect has been linked to activation of intracellular survival pathways, although the mechanism remains unclear. Continuous erythropoietin receptor activator (CERA) is an erythropoietin with a unique pharmacologic profile and long half-life. We hypothesized that pretreatment with CERA would be renoprotective in the cecal ligation and puncture (CLP) model of sepsis-induced AKI. Methods Rats were randomized into three groups: control; CLP; and CLP+CERA (5 μg/kg body weight, i.p. administered 24 h before CLP). At 24 hours after CLP, we measured creatinine clearance, biochemical variables, and hemodynamic parameters. In kidney tissue, we performed immunoblotting—to quantify expression of the Na-K-2Cl cotransporter (NKCC2), aquaporin 2 (AQP2), Toll-like receptor 4 (TLR4), erythropoietin receptor (EpoR), and nuclear factor kappa B (NF-κB)—and immunohistochemical staining for CD68 (macrophage infiltration). Plasma interleukin (IL)-2, IL-1β, IL-6, IL-10, interferon gamma, and tumor necrosis factor alpha were measured by multiplex detection. Results Pretreatment with CERA preserved creatinine clearance and tubular function, as well as the expression of NKCC2 and AQP2. In addition, CERA maintained plasma lactate at normal levels, as well as preserving plasma levels of transaminases and lactate dehydrogenase. Renal expression of TLR4 and NF-κB was lower in CLP+CERA rats than in CLP rats (p<0.05 and p<0.01, respectively), as were CD68-positive cell counts (p<0.01), whereas renal EpoR expression was higher (p<0.05). Plasma levels of all measured cytokines were lower in CLP+CERA rats than in CLP rats. Conclusion CERA protects against sepsis-induced AKI. This protective effect is, in part, attributable to suppression of the inflammatory response.
References
[1]
Chvojka J, Sykora R, Karvunidis T, Raděj J, Krou？ecky A, et al. (2010) New developments in septic acute kidney injury. Physiol Res 59: 859–869.
[2]
Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, et al. (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29(7): 1303–1310.
[3]
Reinhart K, Meisner M, Brunkhorst FM (2006) Markers for sepsis diagnosis: what is useful? Crit Care Clin 22(3): 503–519, ix–x.
[4]
Umegaki T, Ikai H, Imanaka Y (2011) The impact of acute organ dysfunction on patients' mortality with severe sepsis. J Anaesthesiol Clin Pharmacol 27(2): 180–184.
[5]
Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, et al. (2007) Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol 2(3): 431–439.
[6]
Leelahavanichkul A, Yasuda H, Doi K, Hu X, Zhou H, et al. (2008) Methyl-2-acetamidoacrylate, an ethyl pyruvate analog, decreases sepsis-induced acute kidney injury in mice. Am J Physiol Renal Physiol 295(6): F1825–1835.
[7]
Lopes JA, Fernandes P, Jorge S, Resina C, Santos C, et al. (2010) Long-term risk of mortality after acute kidney injury in patients with sepsis: a contemporary analysis. BMC Nephrol 11: 9.
[8]
Grenz A, Dalton JH, Bauerle JD, Badulak A, Ridyard D, et al. (2011) Partial netrin-1 deficiency aggravates acute kidney injury. PLoS One 6(5): e14812.
[9]
El-Achkar TM, Huang X, Plotkin Z, Sandoval RM, Rhodes GJ, et al. (2006) Sepsis induces changes in the expression and distribution of Toll-like receptor 4 in the rat kidney. Am J Physiol Renal Physiol 290(5): F1034–1043.
[10]
Buer J, Balling R (2003) Mice, microbes and models of infection. Nat Rev Genet 4(3): 195–205.
[11]
O'Sullivan AW, Wang JH, Redmond HP (2009) NF-kappaB and p38 MAPK inhibition improve survival in endotoxin shock and in a cecal ligation and puncture model of sepsis in combination with antibiotic therapy. J Surg Res 152(1): 46–53.
[12]
Liu SF, Malik AB (2006) NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 290(4): L622–L645.
[13]
Grinevich V, Knepper MA, Verbalis J, Reyes I, Aguilera G (2004) Acute endotoxemia in rats induces down-regulation of V2 vasopressin receptors and aquaporin-2 content in the kidney medulla. Kidney Int 65(1): 54–62.
[14]
Escalante BA, Ferreri NR, Dunn CE, McGiff JC (1994) Cytokines affect ion transport in primary cultured thick ascending limb of Henle's loop cells. Am J Physiol 266(6 Pt 1): C1568–1576.
[15]
Kohan DE (1994) Interleukin-1 regulation of collecting duct prostaglandin E2 and cyclic nucleotide accumulation. J Lab Clin Med 123(5): 668–675.
[16]
Husted RF, Zhang C, Stokes JB (1998) Concerted actions of IL-1βeta inhibit Na+ absorption and stimulate anion secretion by IMCD cells. Am J Physiol 275(6 Pt 2): F946–954.
[17]
Walden AP, Young JD, Sharples E (2010) Bench to bedside: A role for erythropoietin in sepsis. Crit Care 14(4): 227.
[18]
Bernhardt WM, Eckardt KU (2008) Physiological basis for the use of erythropoietin in critically ill patients at risk for acute kidney injury. Curr Opin Crit Care 14(6): 621–626.
[19]
Fox AC, Coopersmith CM (2009) Erythropoietin in sepsis: a new use for a familiar drug? Crit Care Med 37(3): 1138–1139.
[20]
Santhanam AV, Smith LA, Akiyama M, Rosales AG, Bailey KR, et al. (2005) Role of endothelial NO synthase phosphorylation in cerebrovascular protective effect of recombinant erythropoietin during subarachnoid hemorrhage-induced cerebral vasospasm. Stroke 36(12): 2731–2737.
[21]
Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, et al. (2003) Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102(4): 1340–1346.
[22]
Moore E, Bellomo R (2011) Erythropoietin (EPO) in acute kidney injury. . Ann Intensive Care 21 1(1): 3.
[23]
Bagnis C, Beaufils H, Jacquiaud C, Adabra Y, Jouanneau C, et al. (2001) Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 16(5): 932–938.
[24]
Sharples EJ, Yaqoob MM (2006) Erythropoietin in experimental acute renal failure. Nephron Exp Nephrol 104(3): e83–88.
[25]
Westenfelder C, Biddle DL, Baranowski RL (1999) Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 55(3): 808–820.
[26]
Johnson DW, Vesey DA, Gobe GC (2010) Erythropoietin Protects Against Acute Kidney Injury and Failure. The Open Drug Discovery Journal 2: 8–17.
[27]
Fujiwara N, Nakamura T, Sato E, Kawagoe Y, Hikichi Y, et al. (2011) Renovascular protective effects of erythropoietin in patients with chronic kidney disease Intern Med 50(18): 1929–34.
[28]
Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, et al. (2006) Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 1(6): 1211–1215.
[29]
Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, et al. (1991) Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 50(6): 702–712.
[30]
Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, et al. (1999) Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10(11): 2392–2395.
[31]
Menne J, Park JK, Shushakova N, Mengel M, Meier M, et al. (2007) The continuous erythropoietin receptor activator affects different pathways of diabetic renal injury. J Am Soc Nephrol 18(7): 2046–2053.
[32]
Meerwein C, Korom S, Arni S, Inci I, Weder W, et al. (2011) The effect of low-dose continuous erythropoietin receptor activator in an experimental model of acute Cyclosporine A induced renal injury. Eur J Pharmacol 671(1-3): 113–9.
[33]
Buras JA, Holzmann B, Sitkovsky M (2005) Animal models of sepsis: setting the stage. Nat Rev Drug Discov 4(10): 854–865.
[34]
Wichterman KA, Baue AE, Chaudry IH (1980) Sepsis and septic shock–a review of laboratory models and a proposal. J Surg Res 29(2): 189–201.
[35]
Villa P, Sartor G, Angelini M, Sironi M, Conni M, et al. (1995) Pattern of cytokines and pharmacomodulation in sepsis induced by cecal ligation and puncture compared with that induced by endotoxin. Clin Diagn Lab Immunol 2(5): 549–553.
[36]
Doi K, Leelahavanichkul A, Yuen PS, Star RA (2009) Animal models of sepsis and sepsis-induced kidney injury. J Clin Invest 119(10): 2868–2878.
[37]
Doi K, Hu X, Yuen PS, Leelahavanichkul A, Yasuda H, et al. (2008) AP214, an analogue of alpha-melanocyte-stimulating hormone, ameliorates sepsis-induced acute kidney injury and mortality. Kidney Int 73(11): 1266–1274.
[38]
Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW (2005) Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 16(11): 3365–3370.
[39]
Fliser D, Bahlmann FH, deGroot K, Haller H (2006) Mechanisms of disease: erythropoietin–an old hormone with a new mission? Nat Clin Pract Cardiovasc Med 3(10): 563–572.
[40]
Schmidt C, H？cherl K, Schweda F, Kurtz A, Bucher M (2007) Regulation of Renal Sodium Transporters during Severe Inflammation. J Am Soc Nephrol 18: 1072–1083.
[41]
Olesen ET, de Seigneux S, Wang G, Lütken SC, Fr？kiaer J, et al. (2009) Rapid and segmental specific dysregulation of AQP2, S256-pAQP2 and renal sodium transporters in rats with LPS-induced endotoxaemia. Nephrol Dial Transplant. 24(8): 2338–49.
[42]
Langenberg C, Bagshaw SM, May CN, Bellomo R (2008) The histopathology of septic acute kidney injury: a systematic review. Crit Care 12(2): R38.
[43]
H？cherl K, Schmidt C, Kurt B, Bucher M (2010) Inhibition of NF-kappaB ameliorates sepsis-induced downregulation of aquaporin-2/V2 receptor expression and acute renal failure in vivo. Am J Physiol Renal Physiol 298(1): F196–204.
[44]
Lerolle N, Nochy D, Guérot E, Bruneval P, Fagon JY, et al. (2010) Histopathology of septic shock induced acute kidney injury: apoptosis and leukocytic infiltration. Intensive Care Med 36(3): 471–478.
[45]
Messmer UK, Briner VA, Pfeilschifter J (1999) Tumor necrosis factor-alpha and lipopolysaccharide induce apoptotic cell death in bovine glomerular endothelial cells. Kidney Int 55(6): 2322–2337.
[46]
du Cheyron D, Parienti JJ, Fekih-Hassen M, Daubin C, Charbonneau P (2005) Impact of anemia on outcome in critically ill patients with severe acute renal failure. Intensive Care Med 31(11): 1529–1536.
[47]
Kalakeche R, Hato T, Rhodes G, Dunn KW, El-Achkar TM, et al. (2011) Endotoxin uptake by s1 proximal tubular segment causes oxidative stress in the downstream s2 segment. J Am Soc Nephrol 22(8): 1505–1516.
[48]
Cohen J (2002) The immunopathogenesis of sepsis. Nature 420(6917): 885–891.
[49]
Hotchkiss RS, Nicholson DW (2006) Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 6(11): 813–822.
[50]
Li X, Hassoun HT, Santora R, Rabb H (2009) Organ crosstalk: the role of the kidney. Curr Opin Crit Care 15(6): 481–487.
[51]
Hori O, Matsumoto M, Kuwabara K, Maeda Y, Ueda H, et al. (1996) Exposure of astrocytes to hypoxia/reoxygenation enhances expression of glucose-regulated protein 78 facilitating astrocyte release of the neuroprotective cytokine interleukin 6. J Neurochem 66(3): 973–979.
[52]
Kaden J, Priesterjahn R (2000) Increasing urinary IL-6 levels announce kidney graft rejection. Transpl Int 13: Suppl 1S34–41.
[53]
Deng J, Kohda Y, Chiao H, Wang Y, Hu X, et al. (2001) Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int 60(6): 2118–2128.
[54]
Daemen MA, van de Ven MW, Heineman E, Buurman WA (1999) Involvement of endogenous interleukin-10 and tumor necrosis factor-alpha in renal ischemia-reperfusion injury. Transplantation 67(6): 792–800.
[55]
Locksley RM, Killeen N, Lenardo MJ (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104(4): 487–501.
[56]
Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, et al. (1999) Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 17: 331–367.
[57]
Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, et al. (2003) Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 37(5): 1043–1055.
[58]
Jansen TC, van Bommel J, Mulder PG, Lima AP, van der Hoven B, et al. (2009) Prognostic value of blood lactate levels: does the clinical diagnosis at admission matter? J Trauma 66(2): 377–385.
[59]
Kao R, Xenocostas A, Rui T, Yu P, Huang W, et al. (2007) Erythropoietin improves skeletal muscle microcirculation and tissue bioenergetics in a mouse sepsis model. Crit Care 11(3): R58.
[60]
Endre ZH, Walker RJ, Pickering JW, Shaw GM, Frampton CM, et al. (2010) Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 77(11): 1020–1030.
[61]
Cicerone RJ, Vest CM (2011) Guide for the Care and Use of Laboratory Animals. Washington (DC): National Academies Press (US).
[62]
Volpini RA, da Silva CG, Costa RS, Coimbra TM (2003) Effect of enalapril and losartan on the events that precede diabetic nephropathy in rats. Diabetes Metab Res Rev 19(1): 43–51.
[63]
Correa-Costa M, Semedo P, Monteiro AP, Silva RC, Pereira RL, et al. (2010) Induction of heme oxygenase-1 can halt and even reverse renal tubule-interstitial fibrosis. PLoS One 5(12): e14298.
